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Abstract
Risperidone is one of the most widely used atypical antipsychotic drugs and is approved for the treatment of
mental disorders (eg. schizophrenia, autism) in children and adolescents. The present study investigated the
repeated treatment effect of risperidone and associated neurotropic mechanism in the phencyclidine (PCP)-induced
hyperlocomotion model in adolescent rats. We examined whether repeated risperidone treatment would cause a
sensitized inhibition of PCP-induced hyperlocomotion in adolescent rats, and whether such a sensitization effect was
mediated by risperidone-induced alterations in Brain-Derived Neurotrophic Factor (BDNF), an important biomarker
which plays a role in neuropathology of schizophrenia and action of antipsychotic medications. Male adolescent
Sprague-Dawley rats (postnatal days [P] 44-48) were first treated with risperidone (0.50 or 1.0 mg/kg, sc) or vehicle
and tested in the PCP (3.2 mg/kg, sc)-induced hyperlocomotion model for 5 consecutive days. Three days later, all
rats were then challenged with risperidone (0.50 mg/kg) and PCP on ~P 51 to assess the potential sensitization effect.
They were then sacrificed 1 day later and BDNF levels in the Prefrontal Cortex (PFC), striatum and hippocampus were
examined using Western blotting. Behaviorally, repeated risperidone treatment progressively increased its inhibition of
PCP-induced hyperlocomotion across the 5 test days. In the subsequent challenge test, rats previously treated with
risperidone 1.0 mg/kg showed a stronger inhibition of the PCP-induced hyperlocomotion than those previously treated
with vehicle, indicating a robust risperidone sensitization. However, no such group differences in the BDNF and its
precursor proteins in any of the three brain regions were found. Therefore, although repeated adolescent risperidone
administration induced a sensitization effect in the PCP-induced hyperlocomotion model in a dose-dependent fashion,
whether BDNF is critically involved in this effect is still unsettled. Future work that directly manipulates BDNF systems
is needed to further investigate this issue.

Keywords: Brain derived neurotrophic factor; Risperidone;
Adolescence drug treatment; Phencyclidine
Introduction
Brain-derived neurotrophic factor (BDNF) is a member of the
neurotrophin family that is widely distributed in the brain with the
highest levels found in the hippocampus and other cortical areas
[1]. It is involved in many functional processes critical for the brain
development and experience-dependent neuroplasticity, such as
neuronal survival, neural migration, differentiation, synapse formation,
and modulation of neurotransmitter synthesis [2-4]. It also plays an
important role in stress response, learning and memory, and actions
of psychoactive drugs [5-7]. Accumulating clinical evidence indicates
that abnormal BDNF expressions may contribute to pathophysiology
of schizophrenia, as the levels of BDNF have been found decreased
in peripheral (blood) and central (brain) systems of patients with
schizophrenia [8-11]. Antipsychotic drugs can also alter the brain
levels of BDNF, and prevent the stress-induced decrease in the levels of
BDNF, indicating that it may also regulate the action of antipsychotic
drugs [12-17].
In recent years, we have used the Conditioned Avoidance
Response (CAR) and phencyclidine (PCP)-induced hyperlocomotion
to examine the long-term treatment effects of antipsychotic drugs
[18-23]. Both tests are known for their high predictive validity for
antipsychotic efficacy, as antipsychotic drugs show a robust suppression
of avoidance response and PCP-induced hyperlocomotion upon acute
drug administration [24,25]. Testing an antipsychotic drug in two
independent tests of antipsychotic activity is necessary to ensure that
any observed antipsychotic effect is not an artifact of any particular
model but reflects the generality of the treatment effect. We have
been particularly interested in how repeated antipsychotic treatment
Biochem & Pharmacol

alters this suppression over time. Such alterations can be manifested
as either tolerance, which is characterized by decreased responsiveness
to a certain drug effect, or sensitization, which is characterized by
increased responsiveness to a drug effect [26]. The typical paradigm
that we developed to study antipsychotic sensitization and tolerance
consists of an induction phase, in which rats are repeatedly treated
with an antipsychotic drug or vehicle for several days and tested for
their avoidance responses and PCP-induced hyperlocomotion, and
an expression phase, in which all rats are given a challenge dose of
the drug and their avoidance and motor activity under PCP is tested
again [18,19,21,22,27]. Using such a paradigm, we show that repeated
treatment of haloperidol or olanzapine progressively increases its
suppression of avoidance responding across the test sessions in the
induction phase, and makes animals more sensitive to these drugs

*Corresponding authors: Gang Hu, MD, Ph.D., Jiangsu Key Laboratory of
Neurodegeneration, Department of Pharmacology, Nanjing Medical University,
140 Hanzhong Road, Nanjing, Jiangsu 210029, P.R. China, Tel: 86-25-86863108;
Fax: 86-25-86863108; E-mail: ghu@njmu.edu.cn
Ming Li, Ph.D., 238 Burnett Hall, Department of Psychology, University of NebraskaLincoln, Lincoln, NE 68588-0308, USA, Tel: 402-472-3144; E-mail: mli2@unl.edu
Received February 21, 2013; Accepted March 26, 2013; Published March 28,
2013
Citation: Shu Q, Hu G, Li M (2013) Is Brain-derived Neurotrophic Factor a Possible
Mechanism Underlying Risperidone Sensitization in Adolescent Rats? Biochem &
Pharmacol S1: 004. doi:10.4172/2167-0501.S1-004
Copyright: © 2013 Shu Q, et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and
source are credited.

Psycho- and Neuropharmacology

ISSN: 2167-0501 BCPC, an open access journal

Citation: Shu Q, Hu G, Li M (2013) Is Brain-derived Neurotrophic Factor a Possible Mechanism Underlying Risperidone Sensitization in Adolescent
Rats? Biochem & Pharmacol S1: 004. doi:10.4172/2167-0501.S1-004

Page 2 of 8
in the expression phase, evidenced by the findings that animals who
have been treated with haloperidol or olanzapine in the induction
phase show a significantly lower avoidance or lower PCP-induced
hyperlocomotion than those treated with vehicle. In contrast, repeated
treatment of clozapine tends to lose its avoidance suppression ability
over time, thus causing a tolerance effect [18,27]. Risperidone (a widely
used atypical antipsychotic drug) also causes a sensitization effect in the
CAR test [23,28,29], but whether it would cause a similar effect in the
PCP-hyperlocomotion test has not been examined. This is an important
issue as it addresses the generality of repeated risperidone treatmentinduced sensitization phenomenon.
Despite the strong demonstration of risperidone sensitization in
the avoidance conditioning task, the neurobiological mechanisms
underpinning such an effect remain elusive. Because risperidone
sensitization likely reflects a consequence of drug-induced brain
changes, and BDNF is one important molecule involved in
antipsychotic drug-induced neuroplasticity, we thus speculated that
risperidone sensitization may depend on the drug-induced alteration of
BDNF in the schizophrenia-related neural circuitry (e.g. the prefrontal
cortex, hippocampus and striatum). In the present study, we tested this
hypothesis by examining the risperidone-induced BDNF protein in
adolescent rats (~P 52). We chose adolescent rats because our recent
work shows that olanzapine or clozapine exposure can induce longterm alterations in responsiveness to antipsychotic treatment during
adolescence in the CAR model [30]. It was of interest to explore
whether risperidone could do the same. The choice of adolescent rats
was also clinically significant as there has been a significant increase
in the number of children and adolescents who are being treated with
antipsychotic drugs in recent decades [31], and we do not know much
about the long-term consequences of such early drug exposure.

Material and Methods
Animals
Male Sprague-Dawley adolescent rats (P 33-37, 101-125 g on the
delivery date, average age=~P 35) from Charles River Inc. (Portage, MI)
were used. They were housed two per cage, in 48.3 cm×26.7 cm×20.3
cm transparent polycarbonate cages under 12-h light/dark conditions
(light on between 6:30 am and 6:30 pm). Room temperature was
maintained at 22 ± 1°C with a relative humidity of 45-60%. Food and
water was available ad libitum. Animals were allowed at least 5 days of
habituation to the animal facility before being used in experiments. All
procedures were approved by the Institutional Animal Care and Use
Committee at the University of Nebraska-Lincoln.

Drugs and choice of dose
The injection solution of phencyclidine hydrochloride (PCP, gift
from National Institute on Drug Abuse Chemical Synthesis and Drug
Supply Program) was obtained by mixing the drug with 0.9% saline.
The dose of PCP (3.2 mg/kg, sc) was chosen based on our previous
work [18,22,24,32]. This dose of PCP is shown to induce a robust
hyperlocomotion effect without causing severe stereotypy [33,34].
Risperidone (RIS) (gift from the NIMH drug supply program) was
dissolved in distilled sterile water with 1.0% glacial acetic acid. Two doses
(0.5 and 1.0 mg/kg) were tested as they have previously been shown
to acutely inhibit PCP-induced hyperlocomotion [24]. Furthermore,
both drugs at these doses give rise to a clinically comparable range
(60%-80%) of striatal dopamine D2 occupancy in rats, which is similar
to values observed in schizophrenic patients [35]. All drugs were
administrated subcutaneously (sc) at 1.0 ml/kg.
Biochem & Pharmacol

Motor Activity Monitoring Apparatus
The motor activity testing apparatus is described in detail elsewhere
[22,24,36]. Sixteen activity boxes were housed in a quiet room. The
boxes were 48.3 cm×26.7 cm×20.3 cm transparent polycarbonate cages,
which were similar to the home cages but were each equipped with a
row of 6 photocell beams (7.8 cm between two adjacent photo beams)
placed 3.2 cm above the floor of the cage. A computer detected the
disruption of the photocell beams and recorded the number of beam
breaks. All experiments were run during the light cycle.

Experimental procedure
Thirty-two adolescent rats (~P 42-43) were first handled, injected
with 1.0% glacial acetic acid sterile water, and placed in the locomotor
activity apparatus for 2 days (30 min/day), so they habituated to
the experimenter’s handling and testing apparatus. They were then
randomly assigned to 1 of 4 groups (n=8 /group): VEH+VEH (1.0%
glacial acetic acid sterile water+saline), VEH+PCP (1.0% glacial acetic
acid sterile water+PCP 3.2 mg/kg, sc), RIS 0.5+PCP (RIS 0.5 mg/
kg+PCP 3.2 mg/kg), and RIS 1.0+PCP (RIS 1.0 mg/kg+PCP 3.2 mg/kg)
and were repeatedly injected with the drugs and tested for locomotors
activity daily for 5 consecutive days. On each test day, they were first
injected with vehicle, RIS 0.5 or 1.0 mg/kg, and then immediately placed
in the boxes for 30 min. At the end of the 30-min period, they were
taken out and injected with PCP (3.2 mg/kg, sc) or saline and placed
back in the boxes for another 60 min. Motor activity was recorded in 5
min intervals throughout the entire 90-min testing session.
Two days after the last RIS test (~P 50), all rats were returned to
the locomotor activity boxes for one re-habituation session (30 min),
followed by the RIS challenge test 1 day later (~P 51). On the challenge
day, all rats were first injected with RIS 0.5 mg/kg and then immediately
placed in the motor activity boxes for 30 minutes. At the end of the
30-min period, rats were taken out and injected with PCP (3.2 mg/kg,
sc) and placed back in the boxes for another 60 min. Motor activity
was recorded for the entire 90-min testing session. One day after the
challenge test (~P 52), rats were sacrificed by live decapitation and their
brains were removed for further analysis [37].

Preparation of protein extracts
Rat brains were quickly removed and the prefrontal cortex (PFC),
striatum and hippocampus were dissected out over ice according to the
brain atlas of Watson and Paxions (5th edition) [38], and were frozen on
dry ice and stored at -80°C for further analysis. Tissues from these areas
were homogenized in ice-cold RIPA buffer, containing 25 mM Tris/HCl
(pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1%
SDS (Thermo Scientific, Rockford, IL) with Protease Inhibitor Cocktail
(Thermo Scientific, Rockford, IL). After centrifugation at 16,000 g for
15 min, the supernatant was collected and protein concentration was
determined using the BCA Protein Assay Kit (Pierce, Rockford, IL).

Western blot analysis
Equal amount of proteins (40 µg/lane) was run on a sodium
dodecyl sulfate (SDS)-12% polyacrilamide gel (Bio-Rad, Hercules,
CA). Proteins were separated by electrophoresis at 80-120 V for
90 min (BDNF and β-actin), then electrophoretically transferred onto
Polyvinylidene Fluoride (PVDF) membranes (Millipore, Billerica,
MA) for 60 min at 300 mA in Tris/glycine buffer in a tank transfer
system (Bio-Rad, Hercules, CA). The PVDF membranes were blocked
with 5% nonfat dry milk in Tris-buffered saline (TBS) for 2 h at room
temperature, and then incubated with primary antibody overnight at
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4C. Immunostaining was carried out using the following antibodies.
For BDNF, the membranes were incubated with a 1:100 dilution of
anti-BDNF polyclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA), which recognizes both the mature form of the BDNF (14
kDa) and its precursor (pro-BDNF, 32 kDa). For β-actin (used as an
internal standard), the membranes were incubated with anti-β-actin
polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA)
with a 1:800 dilution. After washed 3 times in TBS with 0.1% Tween
20 (TBST) at a 10-min interval, the membranes were incubated with
Odyssey anti-rabbit and anti-goat secondary antibodies (Li-COR
Biosciences, Lincoln, NE), respectively, with 1:5000 dilutions in TBST
at room temperature. After 1 h, the membranes were washed 3 times at
a 10-min interval. Then the bands were visualized and quantified using
Odyssey Fc Imager (Li-COR Biosciences, Lincoln, NE) according to the
manufacturer’s instruction.

Statistical Analysis
Four rats (1 each from the VEH+VEH and RIS 1.0+PCP groups,
and 2 from the VEH+PCP) were identified as outliers based on the
motor activity in the repeated drug test phase by the IBM®SPSS v19
program, and their data were excluded from subsequent data analysis.
Motor activity data from the 5 drug test days were analyzed using
repeated measures ANOVA (the between-subjects factor:drug group;
the within-subjects factor:test day), followed by post hoc LSD tests to
examine group difference. Differences between Day 1 and Day 5 during
the adolescent drug test phase in individual groups were analyzed using
a two-way (day×block) repeated measures ANOVA. Group differences
on the challenge test were examined using a one-way ANOVA
followed by post hoc Tukey tests. The BDNF protein was quantified by
normalizing to β-actin which was re-probed on the same membrane
and then calculated as percentage of the corresponding control group
(deemed to be 100%). Group and regional differences on the BDNF
protein were analyzed using repeated measures ANOVA [4 (group)×3
(region)], followed by post hoc Tukey tests.

Results
Motor activity data
Five repeated drug test days: Figure 1A shows the mean motor
activity of the four groups of rats during the 30-min test period before
PCP or vehicle injection throughout the 5 days of drug testing. Twoway repeated measures ANOVA revealed a main effect of group, F(3,
24)=10.295, p<0.001, and a main effect of test day, F(4, 96)=36.828,
p<0.001, and a significant group×day interaction, F(12, 96)=2.811,
p=0.002. Post hoc Tukey tests revealed that the two RIS groups had
significantly lower motor activity than the VEH+VEH group, all
ps<0.003, suggesting that RIS had a suppression of spontaneous motor
activity. Interestingly, the VEH+PCP group also had significantly lower
motor activity in this 30-min period before PCP injection than the
VEH+VEH group, p=0.020, indicating that rats in the PCP withdrawal
state exhibited a decreased motor activity which may resemble negative
symptoms of schizophrenia.
Figure 1B shows the mean motor activity of the four groups of rats
during the 60-min test period after PCP or vehicle injection throughout
the 5 days of drug testing. Two-way repeated measures ANOVA
revealed a main effect of group, F(3, 24)=123.664, p<0.001, and a main
effect of test day, F(4, 96)=5.508, p<0.001, and a significant group×day
interaction, F(12, 96)=5.738, p<0.001. Post hoc Tukey tests revealed that
the VEH+PCP group had significantly higher motor activity than the
VEH+VEH group, p<0.001, indicating a strong psychomotor activation

Biochem & Pharmacol

effect of this dose of PCP. The two RIS groups had significantly lower
motor activity than the VEH+PCP group, all ps<0.001, confirming the
inhibitory effect of RIS treatment on PCP-induced hyperlocomotion.
The inhibition by RIS 1.0 mg/kg was rather strong, as the RIS 1.0+PCP
group had a comparable level of motor activity to that of the VEH+VEH
group, p=0.499.

Re-habituation session
On the re-habituation day, all rats were placed in the motor activity
boxes for 30 min with no drug treatment (Figure 1C). Rats previously
treated with RIS showed much higher motor activity than the other
groups. One-way ANOVA showed the group effect was marginally
significant, F(3, 24)=2.973, p=0.052. Two group comparisons found
that the two RIS groups differed significantly from the VEH+PCP
group, ps<0.031, suggesting a compensatory rebound effect against the
motor inhibitory effect of RIS during the drug withdrawal.

Challenge test (sensitization assessment)
On the RIS challenge test, all rats were injected with RIS 0.5 mg/kg
first, 30 min later, followed by PCP 3.2 mg/kg. In the first 30 min before
the PCP injection, the two RIS groups had lower motor activity than
the VEH+VEH group. One-way ANOVA showed the group effect was
marginally significant, F(3, 24)=2.922, p=0.055.
In the 60 min after the PCP injection, the group difference
was significant, F(3, 24)=4.922, p=0.008. Post hoc Tukey tests
indicated that the RIS 1.0+PCP group had significantly lower motor
activity than the VEH+PCP group, p=0.012, and significantly lower
motor activity than the RIS 0.5+PCP group, p=0.022, suggesting
that prior treatment of risperidone dose-dependently enhanced
animals’ sensitivity to this drug in inhibiting PCP-induced
hyperlocomotion, a clear sign of risperidone sensitization (Figure 1).

BDNF Data

As shown in figure 2, there did not appear to be any group and
regional differences on the BDNF protein levels. Two-way repeated
measures ANOVA with the group as the between-subjects factor and
brain site (eg. PFC, hippocampus and striatum) as the within-subjects
factors did not find a main effect of group, F(3, 24)=0.141, p=0.934, a
main effect of brain site, F(2, 48)=0.463, p=0.632, or their interaction,
F(6, 48)=0.338, p=0.913. Similarly, no significant group and regional
differences on the Pro-BDNF proteins were observed. Two-way
repeated measures ANOVA failed to find a main effect of group, F(3,
24)=0.141, p=0.934, a main effect of brain site, F(2, 48)=0.373, p=0.691,
or their interaction, F(6, 48)=0.106, p=0.995 (Figures 2 and 3).

Discussion
This study examined the long-term behavioral effects of repeated
risperidone treatment in adolescent rats in the PCP-induced
hyperlocomotion model, a well-known test for antipsychotic activity.
Using a two-phase paradigm (i.e. an induction phase and an expression
phase), we demonstrated that repeated administration of risperidone
dose-dependently increased its inhibition of the PCP-induced
hyperlocomotion across the 5 drug test sessions. In the challenge
test, under the influence of risperidone 0.5 mg/kg, the previously
risperidone-treated group (RIS 1.0+PCP) still exhibited a significantly
higher inhibition of the PCP-induced hyperlocomotion than the drug
naïve group (VEH+PCP). Both findings demonstrated that for the first
time, a sensitization effect could be induced by repeated risperidone
treatment in adolescent rats in the PCP-induced hyperlocomotion
model. However, BDNF protein levels in the PFC, striatum and
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Figure 1: Repeated treatment effect of risperidone on the PCP-induced hyperlocomotion. Locomotor activity throughout the 5 risperidone (0.5 and 1.0 mg/kg) test days
was expressed as Mean+SEM and measured for 30 min before the vehicle or PCP (3.2mg/kg) injection (A) and 60 min after the vehicle or PCP injection (B). Locomotor
activity measured for 30 min on the re-habituation day is presented in (C). Locomotor activity on the challenge test day during the first 30-min test period after the
risperidone (0.5mg/kg, sc) injection and 60-min after the PCP injection is presented in (D) and (E), respectively.
*p < 0.05 relative to the VEH+VEH group;
#p<0.05 relative to the VEH+PCP group;
p<0.05 relative to the RIS1.0+PCP group.

hippocampus did not show any significant group differences, a finding
not paralleled to the behavioral results. Therefore, it appears that prior
repeated risperidone treatment did not cause a significant change in the
BDNF protein level that could support risperidone sensitization.
Previous work has shown that acute administration of many
antipsychotic drugs inhibits the hyperlocomotor activity induced by
acute administrations of PCP in adult animals [34,36,39]. Our recent
work has focused on how repeated antipsychotic treatment affects the
PCP-induced hyperlocomotion over time [18,22,24,32]. We and others
show that in adult rats, repeated haloperidol, olanzapine or clozapine
treatment, but not anxiolytic (eg. chlordiazepoxide) nor antidepressant
treatment (eg. fluoxetine and citalopram) progressively potentiates
their inhibition of PCP-induced hyperlocomotion across sessions and
prolongs this action within sessions [24,32,40]. When the long-term
effects are assessed in a subsequent challenge test, adult rats previously
treated with olanzapine show an enhanced response to olanzapine (i.e.
sensitization), while those previously treated with clozapine show a
decreased response (i.e. tolerance) [18]. The present study extended
this line of research into risperidone and showed that risperidone
shares a similar behavioral profile with olanzapine but not with
clozapine, possibly due to their similar receptor binding profiles against
dopamine D2 receptors and 5-HT2 receptors [41]. Furthermore, this
Biochem & Pharmacol

study extended our previous work into adolescent animals and showed
that even adolescent rats exhibited risperidone-induced alterations in
antipsychotic response. This new finding is in principle consistent with
our recent study showing that olanzapine sensitization could be induced
in adolescent rats in a conditioned avoidance response model [20],
indicating the generality of antipsychotic sensitization independent of
any particular behavioral model.
On the re-habituation day, we noticed that rats previously treated
with risperidone were more active than those treated only with vehicle,
indicating some kind of compensatory rebound when the inhibitory
effect of risperidone was taken off. Risperidone has a strong antagonist
action against dopamine D2 receptor and repeated administration
could cause an increase of D2 receptor density in the prefrontal cortex,
striatum (eg. caudate-putamen, nucleus accumbens), and hippocampus
[42]. In adolescent rats, it has been reported that repeated treatment
of risperidone (0.3, 1.0 and 3.0 mg/kg) for 3 weeks dose-dependently
increased D2 receptor density in the medial prefrontal cortex and
hippocampus [37]. The high dose of risperidone (3.0 mg/kg) also
increased D2 receptors in the striatum [37]. This rebound in motor
activity under drug-free may reflect antipsychotic withdrawal-induced
behavioral hypersensitivity – a state of dopamine supersensitivity that
is characterized by increased behavioral responses to the psychomotor
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Figure 2: BDNF protein levels and representative blots in the prefrontal cortex (PFC) (A), striatum (B) and hippocampus (C) in the four groups of rats previously treated
with sterile water, risperidone 0.5 or 1.0 mg/kg, and PCP 3.2 mg/kg for 5 days and challenged with RIS 0.5 mg/kg+PCP 3.2 mg/kg 3 days later. All rats were sacrificed
1 day after the challenge test and BDNF levels were measured by Western Blotting. Group data (Mean+SEM, n=6-8) are expressed as percentage of mean values in
the VEH+VEH group.

stimulating effects of dopamine agonists such as amphetamine or
apomorphine thought to result from hypersensitivity of dopamine D2
(especially D2high) receptors [43-47]. A similar effect has been observed
in human patients and is termed “neuroleptic-induced supersensitivity
psychosis” [48,49]. Future work needs to determine the reliability of
such an effect and its clinical implications.
BDNF is a member of neurotrophin family. Due to its important
role in the regulation of the brain development and functions, and
schizophrenia is thought to be a neurodevelopmental disorder, it
attracts a fair amount of interest as etiological factor of schizophrenia
and a potential therapeutic target [8,50,51]. A recent meta-analysis
study examining blood BDNF levels in schizophrenia compared to
age-matched healthy controls suggests that reduced blood BDNF levels
in schizophrenia is a rather consistent finding [9]. Decreased BDNF
levels in cortical areas and hippocampus in patients with schizophrenia
has also been reported [52], consistent with findings from various
animal models [8,12,50]. Human studies on the medication effects
often report no significant effects of medications on the peripheral
and central BNDF proteins, including risperidone [9,51,53]. However,
animal work suggests that antipsychotics such as haloperidol, clozapine
and high dose of risperidone (eg. 4.11 mg/kg) tend to decrease BDNF
expression in the rat hippocampus [12,13,54] (but see [14]). Some even
report that risperidone and haloperidol reduce BDNF in the frontal
cortex [13]. Low dose of risperidone with acute and chronic treatment
was without effect on the hippocampal BDNF [54]. Based on these
findings, it is suggested that antipsychotic medications are unable to
reverse the decreased BDNF levels in patients with schizophrenia [9]
and the therapeutic properties of antipsychotic drugs are not mediated

Biochem & Pharmacol

by stimulation of BDNF [12]. In the present study, we also did not
observe any significant changes of BDNF protein in the prefrontal
cortex, hippocampus and striatum that could be attributed to 5 days of
repeated risperidone treatment, indicating that this neurotrophin is not
likely to be an important molecule involved in risperidone sensitization.
The lack of risperidone effect on the brain BDNF could be due
to several factors, of which several methodological issues are worth
being discussed. The first one is that our subjects were adolescent rats
who have different BDNF intrinsic levels and sensitivity to external
stimulations than adult animals [55,56]. Therefore, risperidone
may affect their brains differently than adult brains, an important
issue worth pursuing. The second factor is that all our animals were
challenged with risperidone (0.5 mg/kg) and PCP (3.2 mg/kg) before
being sacrificed. The measured BDNF levels may have been altered by
the acute exposure to risperidone and PCP, thus potentially masking
any BDNF changes induced by prior risperidone treatment. Indeed,
Lipska et al. [12] shows that acute clozapine and haloperidol decreased
hippocampal BDNF levels in normal adult rats, but had either no
effect or further lowered BDNF mRNA levels in the brains of rats with
neonatal lesions of the ventral hippocampus, a validated animal model
of schizophrenia. Our finding that repeated risperidone treatment did
not alter BDNF protein levels in the prefrontal cortex, hippocampus
and striatum in the rats repeatedly treated with PCP is consistent with
this finding, and with the finding that repeated PCP treatment does not
alter BDNF in adolescent brains [57]. Future work examining brain
BDNF levels, as well as the density of BDNF receptors (TrkB, pTrkB,
p75, truncated TkB) in these regions under the drug free condition is
necessary to identify the true impact of prior antipsychotic treatment
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Figure 3: Pro-BDNF protein levels and representative blots in the prefrontal cortex (PFC) (A), striatum (B) and hippocampus (C) in the four groups of rats previously
treated with sterile water, risperidone 0.5 or 1.0 mg/kg, and PCP 3.2 mg/kg for 5 days and challenged with RIS 0.5 mg/kg+PCP 3.2 mg/kg 3 days later. All rats were
sacrificed 1 day after the challenge test and pro-BDNF levels were measured by Western Blotting. Group data (Mean+SEM, n=6-8) are expressed as percentage of
mean values in the VEH+VEH group.

on this molecule and its receptors. Furthermore, to make sure that
BDNF participates in the antipsychotic sensitization mechanisms, one
can block the BDNF receptors with an antagonist (eg. K252a) or test
antipsychotic drugs in BDNF knockout mice.
Taken together, the present study showed that adolescent repeated
risperidone administration induced a sensitization effect in the PCPinduced hyperlocomotion model in a dose-dependent fashion. This
sensitization effect is similar to the one observed in the conditioned
avoidance response model in adult animals [28,58], suggesting that
it might be an intrinsic effect associated with repeated risperidone
treatment. The neurobiological mechanisms responsible for risperidone
sensitization are still not clear. Further studies are needed to determine
whether BDNF is critically involved in the risperidone sensitization.
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